These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16359723)

  • 21. Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models.
    Ramos AT; Troncone LR; Tufik S
    Neuroendocrinology; 2006; 84(5):309-16. PubMed ID: 17135717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of interaction between etifoxine and CRF1 and CRF2 receptors in rodents.
    Verleye M; André N; Gillardin JM
    Neurosci Res; 2006 Sep; 56(1):53-60. PubMed ID: 16769145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.
    Stachowicz K; Gołembiowska K; Sowa M; Nowak G; Chojnacka-Wójcik E; Pilc A
    Neuropharmacology; 2007 Nov; 53(6):741-8. PubMed ID: 17870136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus.
    Marini F; Pozzato C; Andreetta V; Jansson B; Arban R; Domenici E; Carboni L
    Brain Res; 2006 Jan; 1067(1):25-35. PubMed ID: 16360122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor.
    Kakui N; Yokoyama F; Yamauchi M; Kitamura K; Imanishi T; Inoue T; Koyama T
    Pharmacol Biochem Behav; 2009 May; 92(3):393-8. PubMed ID: 19167420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
    Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in rat pup ultrasonic isolation calls induced by lindane.
    Rivera S; Sanfeliu C; García M; Comellas F; Rodríguez-Farré E
    Neurotoxicology; 1992; 13(1):235-9. PubMed ID: 1380684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiogenic role of vasopressin during the early postnatal period: maternal separation-induced ultrasound vocalization in vasopressin-deficient Brattleboro rats.
    Varga J; Fodor A; Klausz B; Zelena D
    Amino Acids; 2015 Nov; 47(11):2409-18. PubMed ID: 26133736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
    Serradeil-Le Gal C; Derick S; Brossard G; Manning M; Simiand J; Gaillard R; Griebel G; Guillon G
    Stress; 2003 Sep; 6(3):199-206. PubMed ID: 13129813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
    Louis C; Cohen C; Depoortère R; Griebel G
    Neuropsychopharmacology; 2006 Oct; 31(10):2180-7. PubMed ID: 16452986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs.
    Hodgson RA; Guthrie DH; Varty GB
    Pharmacol Biochem Behav; 2008 Jan; 88(3):341-8. PubMed ID: 17928040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.
    Engin E; Treit D
    Neuropeptides; 2008 Aug; 42(4):411-21. PubMed ID: 18508119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
    J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M; Dekeyne A; Papp M; Millan MJ
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M
    Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
    Gannon RL; Millan MJ
    Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.